Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04325425 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Study acronym: FOLFIRINEC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 1, 2024 to Sep 2029 Completion date: Sep 1, 2026 to Sep 2029 · Eligibility criteria revisedv4 Show 2 more changesShow less
    • Completion date: Sep 1, 2026 to Sep 2029
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 1 to 6v3
  3. Lead sponsor: Federation Francophone de Cancerologie Digestive to Centre Hospitalier Universitaire Dijon Trial status: Not Yet Recruiting to Recruitingv2 Show 1 more changeShow less
    • Trial status: Not Yet Recruiting to Recruiting
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of GEP or unknown origin. Furthermore, in order to get insights in the putative predictive biomarkers of efficacy of these two regimens, an effort toward a precise molecular characterization of these tumors is required in order to be able to define which subgroup of G3 NEC needs to be treated by which chemotherapy regimen. The FOLFIRINEC trial is set up in order to try to answer these questions
Trial Details
NCT Number NCT04325425
Lead Sponsor Centre Hospitalier Universitaire Dijon
Collaborators: National Cancer Institute, France
Conditions Neuroendocrine Carcinoma
Enrollment 218 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov